ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors

Summary

This is a Phase 1/2, multi-center, open-label study of CPI-1205 + ipilimumab in patients with histologically or cytologically confirmed advanced solid tumors. This study is designed to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of CPI-1205 + ipilimumab in patients with advanced solid tumors. Patients in Phase 2 will be treated at the RP2D of CPI-1205 + ipilimumab. This study was stopped prior to proceeding to Phase 2; no patients were enrolled in Phase 2.

Timeline

Start

2017-12-14

Primary completion

2019-06-12

Completion

2019-06-12

Drugs

Indications